Journal: bioRxiv
Article Title: Succinate Dehydrogenase loss causes cascading metabolic effects that impair pyrimidine biosynthesis
doi: 10.1101/2025.02.18.638948
Figure Lengend Snippet: Temporal measurements of aspartate levels and cell proliferation upon treatments that constrain aspartate acquisition reveals distinct patterns. a. Model depicting three methods of inducing aspartate limitation in cells. Complex I inhibition with rotenone blocks NAD+ regeneration thereby slowing TCA cycling; GOT1/2 double knockout (DKO) blocks transamination of oxaloacetate (OAA) to generate aspartate; and atpenin A5 (AA5) inhibits succinate dehydrogenase (SDH) activity, directly blocking the oxidative TCA cycle upstream of aspartate synthesis. b. GFP/RFP ratio of 143B jAspSnFR3/NucRFP cells treated with a rotenone titration, with one condition cultured with 1 mM pyruvate (+PYR), in DMEM without pyruvate (n=4). c. NucRFP counts per well of 143B jAspSnFR3/NucRFP cells treated with a rotenone titration, with one condition cultured with 1 mM pyruvate in DMEM without pyruvate (n=4). d. GFP/RFP ratio of 143B jAspSnFR3/NucRFP GOT1/2 double knockout (DKO) cells against a titration of environmental aspartate concentrations in DMEM without pyruvate (n=4). e. NucRFP counts of 143B jAspSnFR3/NucRFP GOT1/2 double knockout (DKO) cells against a titration of environmental aspartate concentrations in DMEM without pyruvate (n=4). f. Model showing that aspartate acquisition and consumption are basally matched at steady state until acquisition is inhibited by either disrupting synthesis through complex I impairment (Rotenone) in WT cells or by double knockout (DKO) of GOT1 and GOT2 DKO) and slowing uptake by environmental aspartate withdrawal (-ASP). Following aspartate acquisition impairments, aspartate levels decay while the rate of aspartate consumption for biosynthesis (measured as cell proliferation) is maintained. When the aspartate pool is depleted to the point that it slows aspartate consumption, cells enter a new steady state at a lower aspartate level, where acquisition and consumption are slowed, but once again matched. g. GFP/RFP ratio of 143B jAspSnFR3/NucRFP cells treated with an AA5 titration in DMEM (n=4). h. NucRFP counts of 143B jAspSnFR3/NucRFP cells treated with an AA5 titration in DMEM (n=4). i. NucRFP counts of 143B jAspSnFR3/NucRFP cells treated with either Veh or 5 µM AA5 with or without 20 mM aspartate in DMEM (n=3). Data are plotted as means ± standard deviation (SD) except g and h which are shown as means ± standard error of the mean (SEM).
Article Snippet: Membranes were blocked with 5% BSA in Tris-buffered saline with 0.1% Tween-20 (TBS-T) and incubated at 4°C overnight with the following antibodies: anti-GOT2 (Proteintech, 14800-1-AP, 1:1000), anti-GOT1 (Cell Signaling, 34423S, 1:1,000), anti-GFP (Sigma, 1:1000), anti-FH (Origene, TA500675S, 1:1000), anti-SDHB (Atlas, HPA002868, 1:1,000), anti-pChk1 (Cell Signaling, 2348S, 1:1000), anti-pChk2 (Cell Signaling, 2197S, 1:1000), anti-GAPDH (Cell Signaling, 5174S, 1:5000), and anti-Vinculin (Sigma, SAB4200729, 1:10,000).
Techniques: Inhibition, Double Knockout, Activity Assay, Blocking Assay, Titration, Cell Culture, Standard Deviation